On May 9, 2025 SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, reported that one abstract on izalontamab brengitecan (iza-bren), a potentially first-in-class EGFRxHER3 bispecific antibody drug conjugate (ADC) will be presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Breast Cancer 2025 Annual Congress taking place May 14 – May 17 in Munich, Germany (Press release, SystImmune, MAY 9, 2025, View Source [SID1234652830]). Iza-bren is being jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive license agreement.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data will be presented at the meeting from an ongoing Ph1 clinical trial of iza-bren in patients with locally advanced or metastatic HER2- Breast Cancer. Additional subgroup analysis in previously disclosed data at SABCS 2024 shows encouraging efficacy for iza-bren across all HER2 levels in HER2- Breast Cancer patients including HER2 0 patients. These data highlights continued progress in iza-bren clinical development and builds upon the previously reported clinical data in breast cancer patients at SABCS in 2024.

"These data continue to support our conviction that iza-bren demonstrates strong clinical efficacy across a wide variety of tumors such as breast cancer including HER2 negative breast cancer with a manageable safety profile," said Jonathan Cheng, M.D., CMO of SystImmune. "This positions iza-bren as an important therapeutic option that may address the unmet medical needs of patients with limited treatment options. We are committed to advancing this therapy through clinical trials, exploring its potential not only as a monotherapy but also in combination with other agents, so as to improve outcomes for cancer patients globally."

Details on the presentations at ESMO (Free ESMO Whitepaper) Breast are below:

Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 Bispecific Antibody-drug Conjugate (ADC), in Patients with Locally Advanced or Metastatic Breast Cancer (BC)
Presentation No: 302MO
Session Title: Mini Oral Session 2
Speaker: Yiqun Du (Shanghai, China)
Session Date & Time: Friday, May 16th, 2025, 8:20 AM-10:10 AM CEST

About iza-bren
The company is developing iza-bren, a bispecific antibody-drug conjugate (ADC) that targets both EGFR and HER3. These proteins are highly expressed in most epithelial tumors. The tetravalent iza-bren has two binding domains for distinct Growth Factor Receptors that drive cancer cell proliferation and survival. Iza-bren blocks EGFR and HER3 signals to cancer cells, reducing proliferation and survival signals. Upon antibody mediated internalization, iza-bren is trafficked to cancer cell lysosomes and liberates its therapeutic payload that induces genotoxic stress activating pathways leading to cancer cell death.